 Vaccines, DNA
"Vaccines, DNA" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
| Descriptor ID |
D019444
|
| MeSH Number(s) |
D12.776.828.868.910 D20.215.894.865.910 D23.050.865.910
|
| Concept/Terms |
Vaccines, DNA- Vaccines, DNA
- Recombinant DNA Vaccines
- DNA Vaccines, Recombinant
- DNA Vaccines
- Naked DNA Vaccines
- DNA Vaccines, Naked
- Vaccines, Naked DNA
- Vaccines, Recombinant DNA
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, DNA".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, DNA".
This graph shows the total number of publications written about "Vaccines, DNA" by people in this website by year, and whether "Vaccines, DNA" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 3 | 1 | 4 | | 2009 | 1 | 1 | 2 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2020 | 1 | 0 | 1 | | 2024 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Vaccines, DNA" by people in Profiles.
-
Kalams SA, Felber BK, Mullins JI, Scott HM, Allen MA, De Rosa SC, Heptinstall J, Tomaras GD, Hu J, DeCamp AC, Rosati M, Bear J, Pensiero MN, Eldridge J, Egan MA, Hannaman D, McElrath MJ, Pavlakis GN. Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119. JCI Insight. 2024 Aug 01; 9(18).
-
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 May; 11(5):e285-e299.
-
Geukes Foppen MH, Rohaan MW, Borgers JSW, Philips D, Vyth-Dreese F, Beijnen JH, Nuijen B, van den Berg JH, Haanen JBAG. Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical Trial. Oncol Res Treat. 2024; 47(7-8):351-359.
-
Guimaraes LC, Costa PAC, Scalzo Júnior SRA, Ferreira HAS, Braga ACS, de Oliveira LC, Figueiredo MM, Shepherd S, Hamilton A, Queiroz-Junior CM, da Silva WN, da Silva NJA, Rodrigues Alves MT, Santos AK, de Faria KKS, Marim FM, Fukumasu H, Birbrair A, Teixeira-Carvalho A, de Aguiar RS, Mitchell MJ, Teixeira MM, Vasconcelos Costa V, Frezard F, Guimaraes PPG. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Nat Commun. 2024 Jan 18; 15(1):590.
-
Li E, Closmann JJ, Jordan RC. Herpes zoster: treatment, management, and prevention with the recombinant DNA vaccine. Gen Dent. 2024 Jan-Feb; 72(1):54-57.
-
Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 07 01; 107(3):487-498.
-
Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl Trop Dis. 2017 May; 11(5):e0005440.
-
Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC. Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice. Cancer Immunol Immunother. 2017 01; 66(1):63-75.
-
Thompson M, Heath SL, Sweeton B, Williams K, Cunningham P, Keele BF, Sen S, Palmer BE, Chomont N, Xu Y, Basu R, Hellerstein MS, Kwa S, Robinson HL. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus. PLoS One. 2016; 11(10):e0163164.
-
Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|